National Bank of Canada
APLS

National Bank of Canada’s Apellis Pharmaceuticals APLS Stock Holding History

National Bank of Canada’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-782,701
Closed -$17.1M – 2986
2025
Q1 		$17.1M Sell
782,701
-602,899
-44% -$16.7M 0.02% 564
2024
Q4 		$44.2M Buy
1,385,600
+1,385,080
+266,362% +$41.7M 0.05% 337
2024
Q3 		$15K Sell
520
-80
-13% -$2.96K ﹤0.01% 1997
2024
Q2 		$21.8K Hold
600
– – ﹤0.01% 1948
2024
Q1 		$25.2K Buy
+600
New +$38.2K ﹤0.01% 1959
2023
Q4 		– Sell
-393
Closed -$14.6K – 2719
2023
Q3 		$14.6K Buy
393
+36
+10% +$1.58K ﹤0.01% 2111
2023
Q2 		$32.5K Buy
+357
New +$30.8K ﹤0.01% 1899

Other funds holding APLS

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

National Bank of Canada's APLS Position: Q2 2025 in Review

National Bank of Canada sold out of Apellis Pharmaceuticals (APLS) in Q2 2025, closing a stake of 782,701 shares — an estimated $17.1M sold.

National Bank of Canada first reported a position in APLS in Q2 2023 and held it in 7 quarters. The position peaked at $44.2M in Q4 2024. 247 funds tracked by Wall St. Rank hold APLS as of Q2 2025.

  • National Bank of Canada reported no remaining Apellis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • National Bank of Canada sold 782,701 Apellis Pharmaceuticals shares in Q2 2025, an estimated $17.1M.
  • National Bank of Canada first reported a position in Apellis Pharmaceuticals in Q2 2023 and held it in 7 quarters.
  • National Bank of Canada's Apellis Pharmaceuticals position peaked at $44.2M in Q4 2024.
  • 247 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2025.

Based on National Bank of Canada's 13F filing for Q2 2025, filed 13 Aug 2025.